Drug General Information (ID: DDIQ3KCS6G)
  Drug Name Hepatitis A Vaccine Drug Info Trastuzumab deruxtecan Drug Info
  Drug Type Vaccine Monoclonal antibody
  Therapeutic Class Vaccines Antineoplastics/Her2 Inhibitors

 Mechanism of Hepatitis A Vaccine-Trastuzumab deruxtecan Interaction (Severity Level: Moderate)
     Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Hepatitis A Vaccine Trastuzumab deruxtecan
      Mechanism Vaccine or toxoid Immunosuppressive effects
      Key Mechanism Factor 1
Factor Name Vaccine/toxoid
Factor Description The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
      Mechanism Description
  • Antagonize the effect of Hepatitis A Vaccine when combined with Trastuzumab deruxtecan 

Recommended Action
      Management In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.

References
1 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
2 Product Information. Imovax Rabies (rabies vaccine). sanofi pasteur, Swiftwater, PA.
3 Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.".